Disease · MONDO_0009693
Comparisons in its trials438
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 438
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events | 581 of 878 | 552 of 878 | 1,756 | NCT00330759 | Trial comparisons |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause | 41 of 879 | 42 of 868 | 1,747 | NCT00869206 | Trial comparisons |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events | 96 of 879 | 103 of 868 | 1,747 | NCT00869206 | Trial comparisons |
| Arm A Part 1 vs Arm B Part 1: Post-Consolidation Stringent Complete Response (sCR) Rate | 110 of 542 | 157 of 543 | 1,085 | NCT02541383 | Trial comparisons |
| Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone: serious adverse events | 198 of 470 | 235 of 474 | 944 | NCT01818752 | Trial comparisons |
| Bortezomib vs Carfilzomib: serious adverse events | 182 of 456 | 272 of 463 | 919 | NCT01568866 | Trial comparisons |
| Breast Cancer 4 Weeks vs Breast Cancer 12 Weeks: Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer | 113 of 410 | 119 of 410 | 820 | NCT00869206 | Trial comparisons |
| Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd): serious adverse events | 221 of 389 | 256 of 392 | 781 | NCT01080391 | Trial comparisons |
| PAN+BTZ vs PBO+BTZ: serious adverse events | 228 of 381 | 157 of 377 | 758 | NCT01023308 | Trial comparisons |
| E-Ld Cohort vs Ld Cohort: deaths from any cause | 240 of 374 | 232 of 374 | 748 | NCT01335399 | Trial comparisons |
| E-Ld Cohort vs Ld Cohort: serious adverse events | 293 of 371 | 279 of 371 | 742 | NCT01335399 | Trial comparisons |
| Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): deaths from any cause | 259 of 369 | 287 of 368 | 737 | NCT02252172 | Trial comparisons |
| Lenalidomide + Dexamethasone (Rd) vs Daratumumab + Lenalidomide + Dexamethasone (DRd): serious adverse events | 262 of 365 | 289 of 364 | 729 | NCT02252172 | Trial comparisons |
| Ixazomib+ Lenalidomide + Dexamethasone vs Placebo + Lenalidomide + Dexamethasone: deaths from any cause | 250 of 361 | 251 of 359 | 720 | NCT01564537 | Trial comparisons |
| Ixazomib+ Lenalidomide + Dexamethasone vs Placebo + Lenalidomide + Dexamethasone: serious adverse events | 205 of 361 | 202 of 359 | 720 | NCT01564537 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS) | 103 of 354 | 50 of 355 | 709 | NCT03710603 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): deaths from any cause | 44 of 354 | 34 of 355 | 709 | NCT03710603 | Trial comparisons |
| Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Overall MRD Negativity Rate | 168 of 354 | 267 of 355 | 709 | NCT03710603 | Trial comparisons |
| Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): deaths from any cause | 217 of 356 | 172 of 350 | 706 | NCT02195479 | Trial comparisons |
| Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): serious adverse events | 117 of 354 | 186 of 346 | 700 | NCT02195479 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009693/comparisons